These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36175267)

  • 1. Re: Jens Bedke, Brian I. Rini, Elizabeth R. Plimack, et al. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. Eur Urol. 2022;82:427-39.
    Zhao B
    Eur Urol; 2022 Dec; 82(6):e174-e175. PubMed ID: 36175267
    [No Abstract]   [Full Text] [Related]  

  • 2. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
    Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
    Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
    Plimack ER; Powles T; Stus V; Gafanov R; Nosov D; Waddell T; Alekseev B; Pouliot F; Melichar B; Soulières D; Borchiellini D; McDermott RS; Vynnychenko I; Chang YH; Tamada S; Atkins MB; Li C; Perini R; Molife LR; Bedke J; Rini BI
    Eur Urol; 2023 Nov; 84(5):449-454. PubMed ID: 37500340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
    N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
    Bedke J; Rini BI; Plimack ER; Stus V; Gafanov R; Waddell T; Nosov D; Pouliot F; Soulières D; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Tamada S; Nguyen AM; Wan S; Perini RF; Rhoda Molife L; Atkins MB; Powles T
    Eur Urol; 2022 Oct; 82(4):427-439. PubMed ID: 35843776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
    Tamada S; Kondoh C; Matsubara N; Mizuno R; Kimura G; Anai S; Tomita Y; Oyama M; Masumori N; Kojima T; Matsumoto H; Chen M; Li M; Matsuda K; Tanaka Y; Rini BI; Uemura H
    Int J Clin Oncol; 2022 Jan; 27(1):154-164. PubMed ID: 34800178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
    Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
    J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
    Ding D; Hu H; Shi Y; She L; Yao L; Zhu Y; Zeng S; Shen L; Huang J
    Oncologist; 2021 Feb; 26(2):e290-e297. PubMed ID: 32918790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO].
    Rexer H; Bedke J
    Urologe A; 2017 Mar; 56(3):385-386. PubMed ID: 28246756
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma.
    Zhu J; Zhang T; Wan N; Liang Z; Li J; Chen X; Liang W; Jiang J
    Immunotherapy; 2020 Dec; 12(17):1237-1246. PubMed ID: 32878521
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China.
    Chen J; Hu G; Chen Z; Wan X; Tan C; Zeng X; Cheng Z
    Clin Drug Investig; 2019 Oct; 39(10):931-938. PubMed ID: 31250401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence.
    Capitanio U; Fallara G; Raggi D; Nocera L; Larcher A; Belladelli F; Rowe I; Briganti A; Salonia A; Karakiewicz P; Montorsi F; Martini A; Necchi A
    Curr Probl Cancer; 2022 Aug; 46(4):100875. PubMed ID: 35679628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Motzer RJ; Penkov K; Haanen J; Rini B; Albiges L; Campbell MT; Venugopal B; Kollmannsberger C; Negrier S; Uemura M; Lee JL; Vasiliev A; Miller WH; Gurney H; Schmidinger M; Larkin J; Atkins MB; Bedke J; Alekseev B; Wang J; Mariani M; Robbins PB; Chudnovsky A; Fowst C; Hariharan S; Huang B; di Pietro A; Choueiri TK
    N Engl J Med; 2019 Mar; 380(12):1103-1115. PubMed ID: 30779531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
    Rini BI; Atkins MB; Plimack ER; Soulières D; McDermott RS; Bedke J; Tartas S; Alekseev B; Melichar B; Shparyk Y; Kondoh C; Langiewicz P; Wood LA; Hammers H; Silber CG; Haber B; Jensen E; Chen M; Powles T
    Eur Urol Oncol; 2022 Apr; 5(2):225-234. PubMed ID: 34244116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [KEYNOTE-426 : Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma].
    Bedke J; Stühler V
    Urologe A; 2020 Jul; 59(7):841-842. PubMed ID: 32458147
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
    Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
    Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Bradley McGregor, Daniel M. Geynisman, Mauricio Burotto, et al. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. Eur Urol Oncol. 2023;6:339-348.
    Chadha J; Chahoud J
    Eur Urol Oncol; 2024 Feb; 7(1):172. PubMed ID: 37357090
    [No Abstract]   [Full Text] [Related]  

  • 19. Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era.
    Numakura K; Muto Y; Naito S; Hatakeyama S; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Obara W; Ohyama C; Tsuchiya N; Habuchi T
    Cancer Med; 2021 Sep; 10(17):5839-5846. PubMed ID: 34313025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
    Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Tarazi JC; Duggan W; Perini R; Thakur M; Fernandez KC; Choueiri TK
    Eur J Cancer; 2021 Mar; 145():1-10. PubMed ID: 33412465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.